SPS
IBRX icon

Susquehanna Portfolio Strategies’s ImmunityBio IBRX Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-393,587
Closed -$968K – 1058
2025
Q3 		$968K Buy
+393,587
New +$1.01M 0.02% 690
2024
Q4 		– Sell
-10,392
Closed -$38.7K – 160
2024
Q3 		$38.7K Hold
10,392
– – ﹤0.01% 344
2024
Q2 		$65.7K Hold
10,392
– – ﹤0.01% 491
2024
Q1 		$55.8K Hold
10,392
– – ﹤0.01% 771
2023
Q4 		$52.2K Buy
+10,392
New +$32.6K ﹤0.01% 986

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Susquehanna Portfolio Strategies's IBRX Position: Q4 2025 in Review

Susquehanna Portfolio Strategies sold out of ImmunityBio (IBRX) in Q4 2025, closing a stake of 393,587 shares — an estimated $968K sold.

Susquehanna Portfolio Strategies first reported a position in IBRX in Q4 2023 and held it in 5 quarters. The position peaked at $968K in Q3 2025. 276 funds tracked by Wall St. Rank hold IBRX as of Q4 2025.

  • Susquehanna Portfolio Strategies reported no remaining ImmunityBio position as of Q4 2025 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 393,587 ImmunityBio shares in Q4 2025, an estimated $968K.
  • Susquehanna Portfolio Strategies first reported a position in ImmunityBio in Q4 2023 and held it in 5 quarters.
  • Susquehanna Portfolio Strategies's ImmunityBio position peaked at $968K in Q3 2025.
  • 276 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2025.

Based on Susquehanna Portfolio Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.